Murray Medical's first day of trading jumped 44% market value is expected to impact the "GEM brother"

On October 16th, Meirui Medical was listed on the Shenzhen Stock Exchange and officially landed on the GEM. As part of the return to privatization of China's general stock, Murray Healthcare was de-listed from the NYSE in 2015. Now, finally return to the domestic capital market.
the IPO, Meirui Medical issued 122 million shares with an issue price of 48.80 yuan per share, raising a total of 5.93 billion yuan, the largest IPO ever made by GEM, breaking the previous record of 5.462 billion yuan set by the Ningde era.'s first day of trading jumped 44%
, founded in 1999, landed on the NYSE in 2006 and was de-listed from the NYSE in 2015 as part of a wave of privatization.
On the morning of October 16th, Wang Lixin, Vice Mayor of Shenzhen City, Li Xiting, Chairman of Meirui Medical, Cheng Ming, President of Meirui Medical, and others attended the listing ceremony held on the Shenzhen Stock Exchange.
the market opened, the company's share price jumped 20 percent to 58.56 yuan per share. Then the in-market stop, after the resumption of trading, Murray Medical quickly closed, as of the close, the company's share price jumped 44% to close at 70.27 yuan / share, a total market value of 85.427 billion yuan.
, the market had widely expected Myer Medical to reach a market value of 130 billion yuan to 150 billion yuan. Some analysts pointed out that according to the current A-share medical device industry average price-earnings ratio of 50 times, After the listing of Meirui Medical, is expected to become the third GEM company to enter the 100 billion yuan market value club after the Ningde era and Wen's shares, and if it can reap four consecutive gains and stops, The market value of Murray Medical or will exceed the Ningde era, become the GEM market value "one brother".the first half of the GEM most
company, Meirui Medical's main medical device research and development, manufacturing, marketing services. The company was listed on the NYSE in 2006 and de-listed from the US in 2015 after 10 years on the market.
Benefiting from the sustained and steady growth of the medical device market and the company's competitive advantage in research and development, production and marketing, in the first half of 2018, Meirui Medical achieved operating income of RMB6.808 billion, up 24.35% YoY;
, according to relevant data, in the first half of 2018, GEM listed companies net profit of more than 1 billion yuan, respectively, only two, light media 2.107 billion yuan and Sanju environmental protection 1.214 billion yuan. In terms of net profit in the first half of 2018 alone, Murray Healthcare ranked first on the GEM.
In addition, according to the company's first three-quarter earnings forecast disclosed in the listing announcement, the company expects operating income of 10.1 billion yuan to 10.45 billion yuan in the January-September 2018 period, up 21.03 percent to 25.23 percent from a year earlier; 2.8 billion yuan to 3 billion yuan, an increase of 40.42 percent to 50.45 percent over a year earlier, and net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses is expected to be 2.75 billion yuan to 2.95 billion yuan, up 36.67 percent to 46.61 percent from a year earlier.
Li Xiting said at the listing ceremony, "Murray Medical is not yet enough to establish the year, we are still a very young company, we have a proactive, with tacit understanding of the management team, there are practical and willing, like-thinking excellent employees, in the medical device industry with broad prospects, we have 10,000 reasons to run the company well!" It
is worth mentioning that the prospectine shows that the funds raised by Meirui Medical will be used for 7 projects, such as the expansion of The Bright Production Base, the construction of the Nanjing Meirui Surgical Products Manufacturing Center, the construction of the Meirui Nanjing Bioreagement Manufacturing Center, the upgrading of the research and development innovation platform, the upgrading of the marketing service system, the construction of information systems, the repayment of bank loans and supplementary operating funds.
Said that in the future, it will continue to work to further reduce medical costs and improve research and development innovation capabilities, while maintaining the cost-effective advantages of the company's products, and actively face the challenges of foreign competitors, and strive to become a world-class leading medical device enterprises. (Securities Daily)